Central Nervous SystemSince the start of M’s Science in 2000, we have been developing sigma-1 receptor agonists for the treatment of CNS disorders. Although we have reconstructed our pipeline, the sigma-1 receptor agonist program is still our main business, and we feel it holds huge potential.
Currently, most drugs used for the treatment of CNS disorders are centered on neurotransmitters and their receptors, and therefore, they can affect various nervous transmission systems within the body. Although these drugs may ameliorate symptoms, they are often not effective for treating the causes and progression of CNS diseases. However, recent neurology research has revealed that the sigma-1 receptor is completely different from many other neurotransmitter receptors. The sigma-1 receptor does not function in neurological transduction, but protects cells from degenerative stress and apoptosis. Thus, sigma-1 receptor agonists are expected to rectify cell damage and rescue neuronal cells. We will continue to develop sigma-1 receptor agonists as a novel type of CNS drug. Our current target diseases for sigma-1 receptor agonists are the chronic neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS).